10-K Decoder · All companies

Monte Rosa Therapeutics, Inc.

GLUE · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$124M$75.6M+63.5%
Operating income−$54.2M−$81.1M+33.2%
Net income−$38.6M−$72.7M+46.9%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026

$Q3 2026Year earlierChange
Revenue$54.4M$12.8M+325%
Operating income−$1.90M−$33.0M+94.2%
Net income$3.10M−$27.1M

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Monte Rosa's revenue in FY2025?
$124M in FY2025 (Fiscal year ended Dec 31, 2025), +63.5% vs $75.6M a year earlier, per its 10-K filed Mar 2026.
Was Monte Rosa profitable in FY2025?
No: net income was −$38.6M and operating income −$54.2M in FY2025.
What was Monte Rosa's revenue in Q3 2026?
$54.4M (+325% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.